Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Brightline 1: A Phase II/III, randomized, open label, multi center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
NCT Number:
NCT05218499
Phase:
II/III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Soft Tissue
Study Objectives:
Study Documents
(MUSC NetID required for document access)